Neovascular AMD Treatment
Neovascular AMD Treatment
The FDA has approved Macugen (pegaptanib sodium injection) for the treatment of wet AMD. Macugen is an anti-angiogenic treatment that is indicated for all types of neovascular AMD, regardless of lesion subtype or size. It is a strand of nucleic acid that targets vascular endothelial growth factor 165, a protein that contributes to the formation of new blood vessels and leakage from blood vessels, the two processes responsible for vision loss associated with wet AMD.
Eyetech and Pfizer have partnered to develop and market Macugen.
The FDA has approved VisionBlue, trypan blue ophthalmic solution, 0.06 percent. VisionBlue is indicated for staining the anterior capsule of the lens during cataract surgery.
Dutch Ophthalmic says the solution will assist surgeons in capsulorhexis procedures in the absence of a red fundus reflex and reduce the risk of complications by enhancing the view of the capsule as it is cut and removed.
It is manufactured by Dutch Ophthalmic Research Center International and is distributed in the United States by Dutch Ophthalmic USA.
Dutch Ophthalmic USA
800-753-8824 or 603-642-8468
Amphastar Pharmaceuticals received FDA approval for Amphadase Injection (hyaluronidase) 150 units per milliliter. Amphadase is a replacement for Wydase, which has been discontinued.
As an enzyme that breaks down hyaluronic acid in connective tissue, hyaluronidase increases tissue permeability and is used as an adjunctive agent to assist in the dispersion and absorption of other drugs. When used in local anesthesia, it increases the area affected and speeds the onset of action in ophthalmic surgery.
According to Amphastar, side effects are mild and include allergic type reactions, similar to those experienced with Wydase.
800-423-4136 or 909-980-9484
Norwood EyeCare has received 501(k) clearance from the FDA for a new 9-millimeter suction ring for its Centurion SES Epikeratome with EpiEdge for Epi-LASIK. The ring secures the Epiker atome to the eye and allows the cornea to protrude through it during Epi-LASIK.
Norwood states that being able to choose between the current 10-mm and new 9-mm ring will enable surgeons to select the ring most suitable for the patient’s eye and that this will reduce the chance of involvement of epithelial stem cells at the limbus, which is of particular importance in patients of Asian ancestry.
866-374-5274 or 678-720-0698
Bausch & Lomb has added Millennium Custom Control Software (CCS) to its Millennium microsurgical phacoemulsification platform. The software offers a lower frequency phaco tip and hyperpulse power modulation for “hyper-cool” phaco energy delivery.
The Millennium CCS features programmable settings that can support a variety of surgical techniques, including standard phaco and bimanual cataract surgery.
The company says the software’s hyperpulse technology (0 to 120 pulses per second) and adjustable duty cycle (that ranges from 10 to 90 percent) allow for control and cutting efficiency, while limiting the amount of heat generated. Its waveform phaco modulation technology is intended to offer balance and coordination between irrigation, aspiration and ultrasound pulses, which the company says reduces the ultrasonic energy delivered to the eye and the possibility of tissue damage within the eye.
Bausch & Lomb
800-828-9030 or 585-338-6000
Volk Optical has introduced the Volk Blumenthal Suturelysis lens for use in all suturelysis procedures. This contact laser lens for use in glaucoma treatment was designed in conjunction with Eytan Blumenthal, MD.
To assist in suture removal, the Blumenthal Suturelysis lens’ convex viewing surface magnifies sutures two to three times, while the pointed lens tip creates a strong compressive force to stabilize the treated area. Volk says this is particularly beneficial in patients with a thick Tenon’s layer or subconjunctival hemorrhage.
800-345-8655 or 440-942-6161